Marella Thorell - 09 Oct 2025 Form 4 Insider Report for ESSA Pharma Inc. (EPIX)

Reporting relationship: Director
Issuer ticker: EPIX
Reported as of: 09 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Oct 2025, 11:55:27 UTC
Prior SEC filing: 11 Feb 2025
Next SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Marella Thorell

Key filing fact

Marella Thorell filed Form 4 for ESSA Pharma Inc. (EPIX) on 15 Oct 2025.

Key facts

This page summarizes Marella Thorell's Form 4 filing for ESSA Pharma Inc. (EPIX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Oct 2025, 11:55.

Change

Previous filing in this sequence was filed on 11 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001826323 Primary reporting owner

Thorell Marella

Relationship: Director
Address: C/O ESSA PHARMA INC., 999 WEST BROADWAY, SUITE 720, VANCOUVER, BRITISH COLUMBIA, CANADA
Signature: /s/ Marella Thorell
Signature date: 15 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EPIX transaction

Common Shares

Disposed to Issuer

Transaction value
Shares: -2,881
Change %: -100%
Price
Shares after: 0
Date: 09 Oct 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the "Agreement"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. ("Purchaser") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right ("CVR") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement.